ArticleClinical drug investigation2018

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Alessandra Iurlo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.